The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1593
ISSUE 1593
March 9, 2020
Issue 1593
- Peanut Allergen Powder (Palforzia)
- Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
- Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
- Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
- Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Peanut Allergen Powder (Palforzia)
March 9, 2020 (Issue: 1593)
The FDA has approved peanut allergen powder-dnfp
(Palforzia – Aimmune) for use as oral immunotherapy
to mitigate allergic reactions, including anaphylaxis,
caused by accidental peanut exposure in patients with
a confirmed peanut allergy. It is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.